Generic of Maxalt® Launches

On December 31, 2012, Apotex received final FDA approval for and commenced shipping the generic equivalent for Merck’s branded product, Maxalt® (rizatriptan benzoate) tablets. Maxalt® had estimated total U.S. annual sales of approximately $336 million.

Maxalt® is indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old.